Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

IMPORTANCE: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not b...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Patrinely, J. Randall, Johnson, Rebecca, Lawless, Aleigha R., Bhave, Prachi, Sawyers, Amelia, Dimitrova, Maya, Yeoh, Hui Ling, Palmeri, Marisa, Ye, Fei, Fan, Run, Davis, Elizabeth J., Rapisuwon, Suthee, Long, Georgina V., Haydon, Andrew, Osman, Iman, Mehnert, Janice M., Carlino, Matteo S., Sullivan, Ryan J., Menzies, Alexander M., Johnson, Douglas B.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2021
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995124/
https://ncbi.nlm.nih.gov/pubmed/33764387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0051
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky